Raydiant Oximetry
CEO: Dr Neil Ray
Raydiant Oximetry is developing a non-invasive fetal pulse oximeter measuring fetal oxygen saturation to accurately predict fetal distress. fetal heart rate monitors lack sensitivity and specificity leading to unnecessary Caesarean sections and emergency procedures. If successful, Raydiant Oximetry’s Lumerah oximeter has already been assigned FDA breakthrough status and has the potential to revolutionize the current standard of fetal and maternal care.